Erlotinib + Gemcitabine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
Aug 1, 2007 → Feb 1, 2009
NCT ID
NCT00518011About Erlotinib + Gemcitabine
Erlotinib + Gemcitabine is a phase 2 stage product being developed by Roche for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00518011. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01782690 | Pre-clinical | Completed |
| NCT00701558 | Phase 2 | Completed |
| NCT00518011 | Phase 2 | Completed |
| NCT00461708 | Phase 2 | Completed |
| NCT02694536 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer